Clinical practice currently uses molecular therapy targeting vascular endothelial growth factor (VEGF) to inhibit the tumor vasculature in cancers including colorectal, lung, and breast cancer [21,22,23]; however, its efficacy is limited by a short treatment response period and the development of drug resistance [24,25,26,27,28]. This evidence concerns the gene VEGFA and neoplasm.